MET and neoplasm: It has been demonstrated that discontinuation of MET tyrosine kinase inhibitors results in increased and prolonged MET activation, coupled to enhanced tumor growth in vitro and in vivo [61], suggesting that MET inhibitors will need to be combined with other therapies [62].